1. Introduction {#s0005}
===============

DNA methylation at the C5 position of cytosine (mC) is a well-characterized epigenetic mark in higher eukaryotes (reviewed in [@bib3], [@bib6], [@bib10], [@bib15]). mC typically confers transcriptional silencing within gene regulatory regions and propagates this silenced state to daughter cells. DNA methylation can be very dynamic *e.g.* during epigenetic reprogramming, early embryonic development and cellular differentiation (reviewed in [@bib29], [@bib31], [@bib46], [@bib49]). During these phases active DNA demethylation, the enzymatic removal of mC, is crucial to shape the epigenetic signature in order to activate key developmental genes (reviewed in [@bib8], [@bib29], [@bib32], [@bib33], [@bib37], [@bib49]). In animals, three main mechanisms of active DNA demethylation have been proposed: DNA demethylation (i) by nucleotide-excision repair (NER; [@bib2]), (ii) by base-excision repair (BER) upon mC deamination by AID (Activation Induced Deaminase; [@bib5], [@bib30]), and (iii) by mC oxidation mediated by the Ten-Eleven Translocation (TET) family enzymes followed by BER ([@bib28], [@bib41], [@bib44]).

A regulatory protein family in NER- and BER-based DNA demethylation is GADD45 (Growth Arrest and DNA Damage Protein 45a,-b,-g). GADD45 proteins are devoid of any obvious enzymatic activity and act as adapters between demethylation target genes and the DNA repair machinery. For example, GADD45a binds to distinct genomic loci *via* the H3K4me3 reader ING1b ([@bib38]), the RNA polymerase cofactor TAF12 ([@bib40]), or the lncRNA TARID ([@bib1]) to recruit DNA repair enzymes such as the 3′-NER endonuclease XPG ([@bib2], [@bib22], [@bib40]), the BER enzyme Thymine DNA Glycosylase TDG ([@bib1], [@bib5], [@bib23]), and AID ([@bib5], [@bib35]).

An important question is whether GADD45 also interacts with TET-mediated, oxidative DNA demethylation. TET dioxygenases iteratively oxidize the methyl group at C5 to yield 5-hydroxymethyl-(hmC) ([@bib21], [@bib44]), 5-formyl-(fC) ([@bib28]) and 5-carboxylcytosine (caC) ([@bib12], [@bib28]). caC can be decarboxylated by bacterial and mammalian C5-DNA methyltransferases *in vitro* ([@bib26]). *In vivo* however, only TDG mediated excision of fC and caC has been shown to accomplish DNA demethylation. The resulting abasic site is processed by BER to incorporate unmethylated C ([@bib5], [@bib12], [@bib28]). Recently it has been shown that GADD45a enhances TDG mediated removal of fC and caC ([@bib23]). Thus, TDG is a common component of both, TET- and GADD45 mediated DNA demethylation. Together with the finding that GADD45a and TDG are required for TET mediated demethylation of *TCF21* ([@bib1]) this raises the question, if Gadd45a may directly interact with TET enzymes.

Here we show that GADD45a and TET1 directly bind each other. Moreover, GADD45a positively regulates TET1 induced mC oxidation and the two proteins require each other for reporter demethylation. Furthermore, GADD45a reduces fC and caC levels, both gene-specifically as well as globally. Our data corroborate a close link between the GADD45a- and TET1-mediated DNA demethylation pathways.

2. Results {#s0010}
==========

We first tested by three independent approaches if GADD45a- and TET-proteins physically interact. First, in co-immunoprecipitation (Co-IP) experiments using overexpressed tagged proteins, both full-length TET1 as well as TET-catalytic-domain-only (TET1~CD~) bound GADD45a ([Fig. 1](#f0005){ref-type="fig"}A; [Supplement Fig. 1](#s0080){ref-type="fn"}A). Second, we used *in-situ* Proximity Ligation Assay (PLA), in which protein--protein interactions are visualized as fluorescent speckles by rolling-circle amplification ([@bib43]). PLA of HA-TET1 with itself (self-PLA) detected the protein expectedly in the nucleus ([Fig. 1](#f0005){ref-type="fig"}B; [@bib44]). Self-PLA of myc-GADD45a showed both cytoplasmic and nuclear staining, consistent with the reported bimodal GADD45a distribution ([Fig. 1](#f0005){ref-type="fig"}C; [@bib7]). PLA between ectopic GADD45a and TET1 showed robust nuclear staining ([Fig. 1](#f0005){ref-type="fig"}D), while no signal was obtained for the control protein NFYC with TET1 ([Fig. 1](#f0005){ref-type="fig"}E). Third, to assess directness of this interaction, we performed Microscale Thermophoresis (MST) binding assays with recombinant proteins. GADD45a specifically bound TET1~CD~, but not control proteins (BSA, IgG; [Fig. 1](#f0005){ref-type="fig"}F). The apparent Kd was in the high nanomolar range (0.55 μM) and comparable to the Kd of GADD45a self-binding (0.57 μM; [Supplement Fig. 1](#s0080){ref-type="fn"}B). This apparently moderate affinity is likely an underestimate, since the active fraction of both recombinant proteins is probably less than 100%, notably for GADD45a after covalent modification with fluorescent dye. Taken together, we conclude that GADD45a and TET1 directly interact.

We next tested for functional cooperation of GADD45a and TET1 in reporter plasmid demethylation, an assay by which the demethylating activity of both proteins can be monitored ([@bib2], [@bib9], [@bib38], [@bib39]). Expression of GADD45a and TET1 both reduced HpaII resistance of an *in vitro* methylated *oct4TK-GFP* reporter plasmid, *i.e.* they restored unmodified cytosine ([Fig. 2](#f0010){ref-type="fig"}A), as expected. Co-expression of GADD45a further enhanced TET1-mediated demethylation ([Fig. 2](#f0010){ref-type="fig"}A) without affecting TET1 protein levels ([Supplement Fig. 2](#s0080){ref-type="fn"}A). Notably, a catalytically inactive TET1 mutant (TET1~CI~) acted dominant negative and impaired GADD45a induced DNA demethylation ([Fig. 2](#f0010){ref-type="fig"}A), eventually competing with endogenous TET1 protein or TET1 interactors.

TET1 carries out iterative oxidation of mC and we aimed to dissect the role of GADD45a in this progression in a time course experiment following transfection. Over the course of 48 h, mC was progressively replaced by unmodified C upon GADD45a or TET1 expression ([Fig. 2](#f0010){ref-type="fig"}B). Combination of TET1 with GADD45a again led to enhanced DNA demethylation, and this became apparent at 30 h and 48 h after transfection. To analyze the underlying mode for this enhanced demethylation we quantified hmC and fC/caC at the demethylated CpG of the reporter using qPCR following MspI restriction on T4 β-glucosyltransferase (β-GT) treated plasmid DNA ([@bib13], [@bib18]). TET1 mediated demethylation was accompanied by a rise in hmC and fC/caC levels, as expected ([Fig. 2](#f0010){ref-type="fig"}C and D). Interestingly, GADD45a co-expression enhanced hmC at early- and reduced it at late time points ([Fig. 2](#f0010){ref-type="fig"}C). The late-phase hmC reduction by GADD45a cannot be explained by impairment of TET1 activity, given the enhanced net demethylation upon GADD45a-TET1 combination ([Fig. 2](#f0010){ref-type="fig"}B). The bimodal kinetics rather suggests that GADD45a promotes not only TET1 activity to produce hmC, but also enhances its processivity to proceed with fC/caC formation, as TET1 tends to stop oxidation at the level of hmC ([@bib24], [@bib44], [@bib48]). fC/caC levels did not accumulate but were reduced by GADD45a at all late time points ([Fig. 2](#f0010){ref-type="fig"}D). This is consistent with the observation that TDG excision of fC/caC is also enhanced by GADD45a ([@bib23]). Hence, the data point to a dual role of GADD45a. First, it promotes the iterative oxidation of mC by TET1 and second, GADD45a enhances the TDG removal of fC/caC, thereby promoting DNA demethylation.

To further analyze the interaction of GADD45a and TET1, we performed loss of function experiments. GADD45a mediated DNA demethylation was strongly impaired by siRNA mediated knockdown of *TET1* ([Fig. 2](#f0010){ref-type="fig"}E). Conversely, TET1 triggered demethylation was fully dependent on endogenous GADD45a ([Fig. 2](#f0010){ref-type="fig"}F), while TET1 protein levels remained unaffected ([Supplement Fig. 2](#s0080){ref-type="fn"}B). These results indicate that GADD45a and TET1 not only cooperate in reporter demethylation, but also require each other.

The previous experiments relied on ectopic expression of GADD45a and TET1. Therefore, we next analysed the endogenous proteins. We observed previously that the *oct4TK-GFP* reporter is demethylated cell-intrinsically upon transfection in HEK293T cells ([@bib2], [@bib38], [@bib39]; see also [Fig. 2](#f0010){ref-type="fig"}A and B). This endogenous demethylation is impaired by knockdown of either *GADD45a* or *TET1*, whereas *siTET2* and *siTET3* showed no effect ([Fig. 2](#f0010){ref-type="fig"}G; see [Supplement Fig. 2](#s0080){ref-type="fn"}C for knockdown). Hence, this endogenous reporter DNA demethylation requires both, GADD45a and TET1, but not TET2 or TET3.

We extended our analysis from reporter genes to endogenous GADD45a target genes. Together with its cofactor, the histone reader ING1b, GADD45a activates a distinct set of methylation-silenced genes including *TCEAL7*, *DHRS2* and *MAGEB2* in HEK293T cells ([@bib38]). These GADD45a targets were also induced by TET1 in a dose-dependent manner ([Fig. 3](#f0015){ref-type="fig"}A). GADD45a-TET1 co-expression led to synergistic gene activation ([Fig. 3](#f0015){ref-type="fig"}A), without affecting unrelated control gene expression ([Supplement Fig. 3](#s0080){ref-type="fn"}A) or TET1 protein levels ([Supplement Fig. 3](#s0080){ref-type="fn"}B). This synergy was specific for catalytically active, full-length TET1 as GADD45a neither cooperated with the TET1-catalytic domain-only (TET1~CD~) variant, nor the TET1~CI~ mutant ([Fig. 3](#f0015){ref-type="fig"}A-B). The lack of TET1~CD~-GADD45a cooperation cannot be explained by the lack of protein interaction as GADD45a still binds TET1~CD~ in MST-binding assays and Co-IP experiments ([Fig. 1](#f0005){ref-type="fig"}F, [Supplement Fig. 1](#s0080){ref-type="fn"}A). The results rather indicate a critical role of the TET1 N-terminus for transcriptional induction of GADD45a targets.

TET proteins can regulate transcription not only by active DNA demethylation but also by recruitment of the O-linked N-acetylglucosamine transferase (OGT) ([@bib4], [@bib42]). However, treatment even with a high dose of the OGT inhibitor alloxan ([@bib20]) did not affect target gene activation by TET1 and GADD45a ([Supplement Fig. 3](#s0080){ref-type="fn"}C), making an involvement of O-GlcNAcylation in this process unlikely. In contrast, the dioxygenase activity of TET1 was required for synergistic gene activation ([Fig. 3](#f0015){ref-type="fig"}B). Therefore, we assayed the formation of hmC and fC/caC within four MspI sites in the *TCEAL7* locus ([Fig. 3](#f0015){ref-type="fig"}C and D) where GADD45a is binding ([Supplement Fig. 4](#s0080){ref-type="fn"}A and [@bib38]). After 24 h of TET1 expression, hmC formed at all CpGs analyzed ([Fig. 3](#f0015){ref-type="fig"}C). Interestingly, hmC at promoter proximal sites (−78 and +34 relative to the transcription start site) was further enhanced by GADD45a+TET1 and appeared precociously after 14 h. This result supports the model that GADD45a facilitates CpG oxidation by TET1. TET1 induced fC/caC predominantly at promoter proximal sites, which was once again reduced by GADD45a ([Fig. 3](#f0015){ref-type="fig"}D), paralleling the findings in reporter analysis ([Fig. 2](#f0010){ref-type="fig"}D). These results support that synergistic target gene activation by active TET1 and GADD45a is accompanied by enhanced hmC formation in proximal CpGs and overall reduced fC/caC levels in the *TCEAL7* locus. However, while the relative changes of induced hmC and fC/caC at the CpG sites analyzed were significant, their absolute levels did not exceed 5% and 1.6%, respectively. This suggests that the strong gene activation stems from only a small subfraction of the cells responding. Consistent with this interpretation, synergistic *TCEAL7* gene activation and hmC production by TET1 and GADD45a were not accompanied by significant *TCEAL7* promoter demethylation, as assayed by HpaII resistance, even at 48 h after transfection ([Supplement Fig. 3](#s0080){ref-type="fn"}D and data not shown).

Since the results pointed to a dual role of GADD45a-promoting TET1 activity and removing fC/caC-we determined global levels of oxidized mC derivatives by quantitative SID-LC-MS/MS (Stable-Isotope Dilution Liquid Chromatography tandem Mass Spectrometry) ([@bib25], [@bib34], [@bib45]). Full-length TET1 or TET1~CD~ strongly induced hmC, fC, and caC in HEK293T cells ([Fig. 4](#f0020){ref-type="fig"}A--D), as expected. Combination of GADD45a with TET1 led to a mild increase in hmC ([Fig. 4](#f0020){ref-type="fig"}B), whereas GADD45a alone had no effect ([Supplement Fig. 4](#s0080){ref-type="fn"}B). GADD45a co-expression with TET1 reduced fC and caC levels ([Fig. 4](#f0020){ref-type="fig"}C and D), consistent with the reporter- ([Fig. 2](#f0010){ref-type="fig"}C) and gene-specific analyses ([Fig. 3](#f0015){ref-type="fig"}D), as well as a recent report ([@bib23]). Notably, this fC/caC reduction was restricted to combined expression of GADD45a with TET1 full-length protein, but not TET1~CD~ ([Fig. 4](#f0020){ref-type="fig"}C and D). These results again support the notion that the increase in hmC and the decrease of fC/caC are two distinct functions of GADD45a, the former requiring the TET1 C-terminal catalytic domain, the latter the TET1 N-terminus.

If GADD45a stimulates TET1 activity, its knockdown should impair TET1 mediated mC oxidation. Therefore, we combined TET1 expression with si*GADD45a*. Depletion of GADD45a reduced hmC formation by TET1 ([Fig. 4](#f0020){ref-type="fig"}E) without affecting TET1 protein level ([Supplement Fig. 2](#s0080){ref-type="fn"}B). The concomitant fC/caC reduction in this context may likely be a consequence of the hmC reduction. Taken together, our data support a model whereby GADD45a positively regulates TET1 activity and enhances fC/caC removal.

3. Discussion {#s0015}
=============

A major unanswered question in DNA demethylation is the relationship of the different pathways proposed. Our results provide the first direct evidence that GADD45a and TET1 mediated DNA demethylation are connected and interdependent. The results support a dual role of GADD45a in TET1 mediated DNA demethylation and we propose that this reflects GADD45a binding and modulation of the two key enzymes in oxidative DNA demethylation, TET1 and TDG. First, GADD45a binds TET1 and positively regulates its activity, thereby enhancing mC oxidation. Elucidating the mechanism of TET1 activation by GADD45a is a highly interesting question to be addressed in future studies, and it may involve *e.g.* more effective TET1 recruitment to target CpGs, TET1 conformational change, or recruitment of cofactors conferred by GADD45a binding. Second, GADD45a reduces fC and caC levels and we propose that this occurs *via* TDG: fC/caC removal by the glycosylase TDG is well-established and GADD45a directly binds TDG ([@bib1], [@bib5], [@bib23]). Importantly, a recent study demonstrated that GADD45a promotes processing of fC/caC by TDG by an unknown mechanism ([@bib23]). This study also showed that knockout of both Gadd45a and Gadd45b from mouse ES cells leads to hypermethylation of specific genomic loci, many of which are also targets of TDG. Hence, GADD45a may function as a bridging protein between TET1 and TDG, thereby physically coupling mC oxidation with repair.

Although the data suggest that GADD45a boosts TET1 mediated DNA demethylation, global mC levels were not affected. This is expected since the bulk of mC arises from constitutively methylated repetitive elements, which mask gene-specific effects of GADD45a (reviewed in [@bib32], [@bib37]). Importantly, the functional cooperation between TET1 and GADD45a may explain the previously observed co-requirement of Gadd45 and Tet1 for demethylation of a number of genes, including *Bdnf IX, Fgf-1b* in mouse brain ([@bib9], [@bib27]), *TCF21* in cancer cells ([@bib1]), and *Oct4*- and *Nanog*-reporters in embryonic stem (ES) cells ([@bib36]).

TET1 has been implicated in both, gene activation and gene repression. In ES cells, loss of Tet1 leads to gene up- and downregulation ([@bib46], [@bib47], [@bib50]). Similarly, in HEK293T cells, TET1 represses and activates a number of genes, however mostly independent of TET1 catalytic activity ([@bib14]). For gene activation with GADD45a the TET1 dioxygenase activity is required ([Fig. 3](#f0015){ref-type="fig"}A and B). This supports that GADD45a can engage TET1 for epigenetic gene activation, *e.g*. by targeting TET1 to specific loci, bridging TDG, or by recruiting cofactors. The fact that transcriptional activation as well as enhanced fC/caC removal are dependent on the TET1 N-terminus ([Fig. 4](#f0020){ref-type="fig"}B) suggests that fC/caC removal might be crucial for transcriptional activation. This is in line with the observation that a single fC or caC stalls RNA polymerase II *in vitro* ([@bib16]).

The link between GADD45a and TET1 raises new questions. What is the mechanism by which GADD45a stimulates TET1 activity and fC/caC removal by TDG? Does GADD45a regulate the pattern of hmC, fC and caC deployment during development? Does combined knockout of Gadd45a and Tet1 affect development in mice? These questions and the greater physiological significance of the GADD45a-TET1 interaction can now be addressed using *e.g.* double-mutant mice.

4. Material and methods {#s0020}
=======================

4.1. Tissue culture, transfection, siRNA treatment {#s0025}
--------------------------------------------------

HEK293T cells were grown at 37 °C in 10% CO2 in Dulbecco\'s Modified Eagle\'s Medium (DMEM), 10% fetal calf serum, 2 mM [l]{.smallcaps}-Glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin. Plasmid DNA was transfected using X-tremeGENE 9 at a DNA:X-tremeGENE ratio of 1:3. 40 nM stealth siGADD45a (Invitrogen) or Dharmacon Smart pools were transfected using Lipofectamine 2000 (Invitrogen) or Dharmafect (Dharmacon) 24 h prior to DNA transfection. For OGT inhibition, 10 mM alloxan was added after transfection and refreshed after 24 h, prior to harvesting after 48 h.

4.2. Expression and reporter constructs and antibodies {#s0030}
------------------------------------------------------

Flag-HA-TET1 was from Addgene (ID 49792; FH-TET1-pEF). The catalytically inactive human TET1^H1672Y/D1674A^ mutation has been described ([@bib9]). The point mutation was introduced in the HxD motif using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) using the following primers: c5519t_a5526c antisense, 5′-ttattcatgttgtgaatggccctgtagggatgagcacagaagtc-3′ c5519t_a5526c sense; 5′-gacttctgtgctcatccctacagggccattcacaacatgaataa-3′. Flag-TET1 catalytic domain (Flag-TET1~CD~, aa1416-2136) was PCR amplified from Flag-HA-TET1 and subcloned into pCS2-2xFlag expression construct. *Oct4TK-GFP* reporter, human pHA-GADD45a and mouse myc-Tet2 expression plasmids have been described ([@bib2], [@bib19]), respectively. Human GADD45a and NFYC coding sequences were PCR amplified and cloned into pCS2+-myc to express N-terminally myc-tagged fusion proteins. Mouse anti-alpha-Tubulin, anti-flag M2, and anti-myc 9E10 were from Sigma Aldrich, rabbit anti-GADD45a from Santa-Cruz, rabbit anti-HA and IgG control from Abcam.

4.3. DNA methylation analysis and T4 β-glucosyltransferase (β-GT) treatment {#s0035}
---------------------------------------------------------------------------

Methylation-sensitive PCR (MS-PCR) was performed as described ([@bib39]). Briefly, HEK293T cells were transfected with *in vitro* methylated *oct4TK-GFP* reporter and/or effector expression plasmids. Plasmid DNA or genomic DNA (gnDNA) was recovered 48 h after transfection or at indicated time points using DNeasy Blood & Tissue kit (Qiagen). Plasmid DNA was split into two parts and digested with either methylation-sensitive HpaII restriction enzyme or PvuII (unrelated control enzyme to fragment the genomic DNA) for 3 h. *Via* qPCR and the Roche Absolute quantification software tool we determined the arbitrary concentrations, taking into account the PCR-efficiency of each individual primer obtained by standard-curve measurements. HpaII resistance in % was determined from the ratio of HpaII digested versus control digested DNA and represents the fraction of modified cytosine residues (mC+hmC+fC+caC). T4 β-glucosyltransferase (β-GT) treatment was performed according to manufacturer\'s instructions (NEB EpiMark Kit). Briefly, reporter plasmid or gnDNA was split into two parts and incubated with or without β-GT for 16 h at 37 °C. Both fractions were again split and digested with PvuII (control) or MspI and analyzed by qPCR. Primer sequences are listed in [Supplementary information](#s0080){ref-type="fn"}. MspI restriction is blocked by fC and caC ([@bib13]). Hence, the ratio of MspI digested vs PvuII digested DNA reflects the combined fraction of fC/caC. β-GT treatment specifically glucosylates hmC, resulting in MspI resistance ([@bib18]). The ratio of MspI digested vs PvuII digested DNA (both +β-GT) thus reflects the combined fraction of hmC/fC/caC. Substraction of fC/caC values (−β-GT) from MspI resistant fraction (+β-GT) results in % hmC.

4.4. Co-immunoprecipitation (Co-IP) {#s0040}
-----------------------------------

48 h after transient TET1 and GADD45a transfection, HEK293T cells were lysed (150 mM NaCl, 20 mM Tris pH 7.5, 2 mM EDTA, 10% glycerol, and cOmplete Mini Protease Inhibitor Cocktail (Roche)) and needle-syringe-homogenized. Following pre-clearing of the lysate by centrifugation and incubation with Agarose G beads (Roche) for 1 h at 4 °C, lysates were incubated on a rotating wheel over night at 4 °C with specific antibody or IgG as control. 2 h after addition of the beads and incubation at 4 °C on a rotating wheel, beads were washed 3 times in lysis buffer and protein was eluted with 4× Laemmli buffer containing ß-Mercaptoethanol. For Western blot analysis, 5% of input was compared to 1/3 of the Co-IP eluate.

4.5. Proximity Ligation Assay (PLA) {#s0045}
-----------------------------------

For visualization of protein--protein interaction *in situ*, Proximity Ligation Assay (PLA) was performed according to manufacturer\'s instructions (Duolink using PLA Technology, Sigma). Briefly, 48 h after transient HA-TET1 and/or myc-GADD45a and myc-NFYC (control protein) transfection, HEK293T cells were fixed in 100% MeOH (Sigma) for 10 min at −20 °C, permeabilized with 0.5% TritonX100 (Sigma) for 10 min, blocked and incubated with primary antibodies anti-HA (Abcam) and anti-myc (Sigma) (both diluted 1:1000) overnight at 4 °C. Then, cells were incubated with respective secondary antibodies (Duolink In Situ PLA Probes Anti-Mouse and Anti-Rabbit both PLUS and MINUS, SIGMA) followed by a ligation and subsequent amplification step to visualize protein interaction by red fluorescence signals (Duolink In Situ Detection Reagents Red, Sigma). To visualize individual proteins by Self-PLA, the respective primary antibody was combined with two secondary antibodies (PLA probes both PLUS and MINUS). Nuclei were counterstained by DAPI-containing mounting medium (Duolink In Situ Mounting Medium with DAPI, Sigma) and analysis was performed using a TCS SP5 confocal microscope (Leica) and 63× oil immersion objective lens. The speckles are likely limited to a fraction of cells due to incomplete transfection efficiency.

4.6. Microscale Thermophoresis {#s0050}
------------------------------

For binding studies, recombinant GADD45a (purified from *E. coli*), recombinant mouse Tet1 (catalytic domain, Active Motif), BSA (Sigma) or IgG (Abcam) were used. GADD45a was labeled with the MonolithTM NT.115 Protein Labeling Kit RED-NHS according to manufacturer\'s recommendations. Concentration of labeled GADD45a was kept constant at 50 nM and mixed with increasing concentrations of Tet1, BSA and IgG (0.1 nM to 5 µM) in a sixteen step 1:1 dilution series in MST buffer (50 mM Tris--HCl pH 7.6, 150 mM NaCl, 10 mM MgCl2 and 0.05% Tween-20). After 15 min of incubation at room temperature, samples were transferred into hydrophilic capillaries and measurements were conducted using a NanoTemper Monolith NT.115 instrument with 60% MST power and 60% LED power. Laser-On time was 30 s, Laser-Off time 5 s. The sigmoidal binding curve fitting was performed according to the law of mass action using NTAnalysis software provided by NanoTemper technologies. No fitting was obtained for GADD45a binding to the negative controls BSA and IgG.

4.7. RT-qPCR {#s0055}
------------

Total RNA was isolated using Qiagen RNeasy mini kit with on-column DNase digest (Qiagen). First strand cDNA was generated using SuperScriptII reverse transcriptase (Invitrogen). Real-Time PCR was performed in technical duplicates using Roche LightCycler480 probes master and primers (see [Supplementary information](#s0080){ref-type="fn"} for primer sequences) in combination with predesigned mono-color hydrolysis probes of the Roche Universal probe library (UPL) or SYBR green. For quantification, the Roche LC480 quantification software module was used. All values were normalized to the level of the housekeeping gene *Gapdh*. Mean values shown were calculated using the mean value of the qPCR replicates from independent experiments (*n*≥3).

4.8. Protein expression and purification {#s0060}
----------------------------------------

*E. coli* BL21-CodonPlus (DE3)-RIL (Stratagene) was transformed with expression constructs encoding C-terminally hexahistidin tagged human GADD45a (pET24b-hGADD45a) and N-terminally hexahistidin-SUMO-tagged Naegleria gruberi Tet1 (pXC1010) ([@bib11]). Cultures were grown at 37 °C to an OD600 of 0.6 and induced with 1 mM isopropyl β-[d]{.smallcaps}-thiogalactopyranoside (IPTG, Thermo Scientific). Protein expression was performed at 16 °C overnight. Pelleted cells were resuspended in lysis buffer (25 mM HEPES/KOH pH 7.6, 0.5 M NaCl, 40 mM Imidazol) and lysed by passage through a Constant Systems LTD cell disrupter (1.8 kbar, constant run). Cell debris were pelleted by centrifugation at 38,400*g* for 30 min and supernatant subjected to a Ni2+-charged chelating sepharose Fast Flow column (GE Healthcare). Bound proteins were eluted by a stepwise gradient of imidazol (60--500 mM) in lysis buffer. Fractions containing pure proteins were concentrated by Vivaspin ultrafiltration devices (GE Healthare). Concentrations of proteins were determined by Bradford assay (Bio-Rad) using BSA as standard.

4.9. Stable-isotope dilution based Liquid Chromatography tandem Mass Spectrometry (LC--MS/MS) {#s0065}
---------------------------------------------------------------------------------------------

The genomic DNA (gnDNA) of HEK293T cells was isolated using DNeasy blood & tissue kit (Qiagen), ethanol precipitated and dissolved in ~dd~H~2~O. 1 µg of gnDNA was degraded with nuclease P1 (Roche Diagnostics, Mannheim, Germany), snake venom phosphodiesterase (Worthington, Lakewood, USA) and alkaline phosphatase (Fermentas, St. Leon-Roth, Germany). All oligonucleotides as well as dC and 5mdC nucleosides were from Sigma Aldrich (Germany). Modified cytidine nucleosides, hmdC, fdC, cadC were purchased from Berry & Associates, Inc. (Dexter, MI). ^15^N~3~-dCTP, ^15^N~3~-dC, ^15^N~5~-dG were from Silantes, GmbH (Munich, Germany). ^2^H~3~-5mdC was from TRC, Inc (Toronto, Canada). ^15^N~3~-5hmdC, ^15^N~3~-5fdC, ^15^N~3~-5cadC, were self-synthesized by a series of *in vitro* reactions (see [Supplementary information](#s0080){ref-type="fn"}). All solutions were prepared using Millipore quality water (Barnstead GenPure xCAD Plus, Thermo Scientific). Quantitative LC--MS/MS analysis of the nucleosides was performed using an Agilent 1290 UHPLC system equipped with ReproSil 100 C18 column (3 µm, 4.6×150 mm^2^, Jasco GmbH, Groß-Umstadt, Germany) and an Agilent 6490 triple quadrupole mass spectrometer, coupled with the stable isotope dilution technique, which allows for accurate quantification ([@bib17], [@bib25], [@bib34], [@bib45]). The details of the procedure are described in [Supplementary information](#s0080){ref-type="fn"}.

4.10. Statistical analyses {#s0070}
--------------------------

Data are expressed as mean values±standard deviation (SD) of biological replicates (*n*≥3). Two-tailed, unpaired Student\'s *t*-test was used to calculate the level of significance. A *p*-value\<0.05 was considered significant. \*, *p*\<0.05; \*\*, *p*\<0.01; \*\*\*, *p*\<0.001. Full listing of *p*-values of the individual experiments is provided in [Supplementary information](#s0080){ref-type="fn"}.
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![GADD45a directly binds TET1. (A) Western blot analysis of co-immunoprecipitation (Co-IP) experiments using protein lysates of HEK293T cells transfected with Flag-HA-TET1 and myc-GADD45a. α-Tubulin was used as specificity control. Input shows 5% of lysate used for IP. (B--E) *In-situ* analysis of TET1-GADD45a interaction by Proximity Ligation Assay (PLA) in HEK293T cells transiently transfected as indicated. Scale bar, 10 µm. (F) Microscale Thermophoresis binding assays of fluorescently labeled recombinant GADD45a to TET1~CD~ or the negative controls BSA and IgG. Concentration of GADD45a was kept constant at 50 nM, while increasing concentrations of TET1~CD~, BSA and IgG were tested (0.1 nM to 5 µM). Each measurement point represents the mean of biological replicates (*n*=3) with error bars as±SD.](gr1){#f0005}

![GADD45a promotes TET1-mediated mC oxidation and reporter DNA demethylation. (A--G) Methylation analysis of *in vitro* methylated *oct4TK-GFP* reporter by methylation sensitive PCR. (A) HEK293T cells were transfected with *oct4TK-GFP* along with empty vector (Ctrl), GADD45a (G45a) or TET1 expression constructs as indicated. Plasmid DNA was recovered 48 h after transfection and subjected to HpaII restriction digest and qPCR. HpaII resistance reflecting the fraction of modified C is displayed. Ctrl, control; TET1~CI~, TET1 catalytically inactive mutant. Bar graphs represent the mean of biological triplicates (*n*=3) with error bars±SD. (B--D) Kinetics of mC and its oxidized derivatives during *oct4TK-GFP* reporter demethylation analyzed by modification-sensitive qPCR. Cells were treated as in (A) and plasmid DNA was recovered at indicated time points after transfection. mC and its oxidized derivatives were analyzed using qPCR following HpaII or MspI restriction digest on T4 β-glucosyltransferase (β-GT) treated or control treated plasmid DNA. In (B), % modified cytosine (mC+hmC+fC+caC) is displayed as % HpaII resistance. (C) and (D) display % hmC and % fC/caC determined by MspI resistance following β-GT treatment and MspI resistance in control treated DNA (without β-GT), respectively. Error bars indicate±SD (*n*=3). (E, F) HEK293T cells were treated as in (A), but pre-transfected with the indicated siRNAs 24 h before DNA transfection. HpaII resistance reflecting the fraction of modified C is displayed. (G) HEK293T cells were transfected with *oct4TK-GFP* without any effector protein with the indicated siRNAs, whereby "mock" represents transfection reagent only. *oct4TK-GFP* plasmid was recovered 72 h after siRNA and 48 h after *oct4TK-GFP* transfection. HpaII cleavage is displayed as % demethylation, reflecting formation of unmodified C. Bar graphs represent the mean of biological triplicates (*n*=3) with error bars±SD. *p*-Values: (\*) *p*\<0.05; (\*\*) *p*\<0.01; (\*\*\*) *p*\<0.001. Complete list of *p*-values in [Supplementary material](#s0080){ref-type="fn"} section.](gr2){#f0010}

![Synergistic target gene activation by GADD45a-TET1 is accompanied by increase in hmC and reduction of fC/caC in promoter CpGs. (A, B) *TCEAL7*, *DHRS2*, *MAGEB2* expression in HEK293T cells upon transfection of empty vector (Ctrl, control), *GADD45a* (G45a) alone or with increasing doses of TET1, catalytic domain only (TET1~CD~), or catalytically inactive TET1 (TET~CI~) as indicated. Relative expression was monitored by qPCR. Bar graphs represent the mean of *n*=4 (A) or *n*=3 (B) experiments with error bars as±SD. (C, D) Kinetics of hmC (C) and fC/caC (D) level changes in the *TCEAL7* locus upon GADD45a and TET expression. HEK293T cells were transfected with empty vector (Ctrl) or GADD45a (G45a) or TET1 as indicated. Genomic DNA was harvested 14 h or 24 h after transfection. hmC and fC/caC were analyzed at positions −2648, −78, +34 and +457 relative to the transcription start site (TSS). Analysis was by modification-sensitive qPCR following MspI restriction on T4 β-glucosyltransferase (β-GT) treated or control treated plasmid DNA. % of MspI resistance following β-GT treatment is displayed as % hmC. % of MspI resistance in control treated DNA (−β-GT) is displayed as % fC/caC. Bar graphs represent the mean of biological triplicates (*n*=3) with error bars as±SD. *p*-Values: (\*) *p*\<0.05; (\*\*) *p*\<0.01; (\*\*\*) *p*\<0.001. Complete list of *p*-values (A--D) in [supplementary material](#s0080){ref-type="fn"} section.](gr3){#f0015}

![GADD45a enhances hmC formation by TET1 and reduces global fC and caC levels. (A--E) SID-LC-MS/MS analysis of mC and its oxidized derivatives in HEK293T cells transiently transfected with empty vector (Ctrl), GADD45a (G45a), and increasing doses of TET1 or its catalytic domain only (TET1~CD~) (A--D). For (E), 24 h prior to DNA transfection, cells were transfected with control or GADD45a specific siRNA and harvested 48 h after DNA transfection. Bar graphs represent the mean of biological replicates (for A--D *n*=3, for E *n*=4) with error bars as±SD. *p*-Values: (\*) *p*\<0.05; (\*\*) *p*\<0.01; (\*\*\*) *p*\<0.001. Complete list of *p*-values (A--E) in [Supplementary material](#s0080){ref-type="fn"} section. N/D, no data.](gr4){#f0020}

[^1]: Equal contribution.
